Pyxis Oncology Inc (PYXS)

$1.06 -0.03 (-2.75%)
Market Cap 65.29M
Revenue (ttm) 16.15M
Net Income (ttm) -77.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -478.82%
Debt to Equity Ratio 0.00
Volume 230,200
Avg Vol 586,936
Day's Range N/A - N/A
Shares Out 61.59M
Stochastic %K 65%
Beta 1.17
Analysts Strong Sell
Price Target $7.20

Latest News on PYXS

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Apr 25, 2025, 1:17 PM EDT - 1 day ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 7:30 AM EDT - 25 days ago

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 4 weeks ago

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 7:30 AM EDT - 5 weeks ago

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Mar 3, 2025, 7:30 AM EST - 7 weeks ago

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Feb 26, 2025, 7:30 AM EST - 2 months ago

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Feb 4, 2025, 7:30 AM EST - 2 months ago

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Dec 19, 2024, 4:08 PM EST - 4 months ago

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Dec 7, 2024, 1:30 AM EST - 5 months ago

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Nov 21, 2024, 9:18 AM EST - 5 months ago

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Nov 20, 2024, 4:05 PM EST - 5 months ago

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Nov 8, 2024, 1:30 PM EST - 6 months ago

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Moment Of Truth Approaches For Pyxis Oncology

Sep 13, 2024, 7:08 AM EDT - 8 months ago

Moment Of Truth Approaches For Pyxis Oncology

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Aug 29, 2024, 7:30 AM EDT - 8 months ago

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Aug 14, 2024, 4:05 PM EDT - 9 months ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Jul 29, 2024, 8:00 AM EDT - 9 months ago

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 28, 2024, 4:30 PM EDT - 10 months ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Jun 10, 2024, 7:30 AM EDT - 11 months ago

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 30, 2024, 7:30 AM EDT - 11 months ago

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

May 14, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

May 9, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Mar 27, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Mar 21, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Mar 7, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 1 year ago

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Nov 7, 2023, 4:30 PM EST - 1 year ago

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Sep 27, 2023, 9:18 AM EDT - 1 year ago

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

Sep 7, 2023, 8:09 AM EDT - 1 year ago

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Aug 31, 2023, 4:01 PM EDT - 1 year ago

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 23, 2023, 8:35 AM EDT - 1 year ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Aug 11, 2023, 7:00 AM EDT - 1 year ago

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Aug 10, 2023, 2:56 PM EDT - 1 year ago

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

Aug 1, 2023, 4:01 PM EDT - 1 year ago

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Jul 10, 2023, 3:01 AM EDT - 1 year ago

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Jun 15, 2023, 8:20 AM EDT - 2 years ago

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

Jun 12, 2023, 2:59 AM EDT - 2 years ago

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

May 30, 2023, 10:52 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

May 30, 2023, 8:30 AM EDT - 2 years ago

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

Pyxis Oncology to Acquire Apexigen

May 24, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology to Acquire Apexigen

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

May 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

Pyxis Oncology: Cashed Up And Entering The Clinic

Mar 27, 2023, 7:32 AM EDT - 2 years ago

Pyxis Oncology: Cashed Up And Entering The Clinic

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Mar 22, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

Mar 16, 2023, 7:30 AM EDT - 2 years ago

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

Feb 13, 2023, 8:00 AM EST - 2 years ago

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

Pyxis Oncology Announces FDA Clearance of Two IND Applications

Dec 1, 2022, 6:45 AM EST - 2 years ago

Pyxis Oncology Announces FDA Clearance of Two IND Applications

Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update

Nov 1, 2022, 6:30 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update

Aug 15, 2022, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update